Patent ductus arteriosus, systemic NT-proBNP concentrations and development of bronchopulmonary dysplasia in very preterm infants: retrospective data analysis from a randomized controlled trial

摘要

Patent ductus arteriosus (PDA) is a common complication in very preterm infants. It is known that there is an association between PDA and development of bronchopulmonary dysplasia (BPD) or death before the postmenstrual age (PMA) of 36?weeks, but this association remains one of the most controversial aspects of the problem. The study aimed to evaluate the relationship between PDA, serum NT-proBNP levels at 2–3 and 8–9?days of life, and BPD/death in very preterm infants. Data of 52 preterm infants with a gestational age 1.5?mm, enrolled in a randomized controlled trial, were used for the retrospective analysis. All patients underwent daily echocardiographic and two serum NT-proBNP measurements within the first 10?days after birth. Two groups of infants were formed retrospectively at PMA of 36?weeks depending on the outcome, BPD (n?=?18)/death (n?=?7) or survival without BPD (n?=?27). Receiver operator characteristic (ROC) curve was used to evaluate the predictive performance of serum NT-proBNP levels for BPD/death occurrence. The percentage of infants who received pharmacological treatment for PDA did not differ between the groups. Based on the area under the ROC curve, serum NT-proBNP levels on the 2–3?day of life (AUC?=?0.71; 95% confidence interval (CI): 0.56–0.9; p?=?0.014)) and on the 8–9?day of life (AUC?=?0.76; 95% CI: 0.6–0.9; p?=?0.002) could reliably predict BPD/death in very preterm infants who had PDA diameter??1.5?mm in the first 72?h of life. Hemodynamically significant PDA (hsPDA) was significantly more often detected in newborns with BPD/death, however, treatment of infants with hsPDA did not reduce the incidence of BPD/death. In very preterm infants with PDA ?1.5?mm at the age of 24–48?h, serum NT-proBNP concentration could reliably predict the development of BPD or death, regardless of the persistence of PDA, with the highest diagnostic value at 8–9?days. This study is registered in ClinicalTrials.gov - NCT03860428 on March 4, 2019.